Morepen Laboratories Enters U.S. Prescription Generics Market via Wholly Owned Arm
Morepen Laboratories Ltd 路 Press Release 路 09 Nov 2026, 2:24 pm
Morepen Laboratories Enters U.S. Prescription Generics Market via Wholly Owned Arm Morepen Laboratories has launched its first prescription generic product, Desloratadine Tablets USP (5 mg), in the U.S. market via its wholly owned subsidiary, Morepen Bio Inc. Building on its established base as a long-standing U.S. Desloratadine API supplier, the move extends Morepen into finished-dosage formulations. Additionally, the company submitted its first ANDA to the U.S. FDA for Sitagliptin Phosphate Tablets USP (25 mg, 50 mg, and 100 mg), which is under review. Morepen plans further U.S. generic filings while evaluating high-potency APIs and oncology.
Original exchange filing (PDF)
More announcements from Morepen Laboratories Ltd
- Update on Credit Rating 路 14 Nov 2026
- Change in Senior Management Personnel on account of resignation 路 31 Oct 2026
- Change in Designation of Senior Management Personnel of the Company 路 28 Oct 2026
- Please find attached the monitoring agency report for the quarter ended September 30, 2026 路 27 Oct 2026
- Please find attached the Investor Presentation for Q2 & H1 FY 27 Financial Results 路 27 Oct 2026
- Please find attached the press release 路 27 Oct 2026
- Please find attached the Q2 & H1 FY 27 Financial Results 路 27 Oct 2026
- Please find attached the Q2 & H1 FY27 Financial Results along with Limited Review Report 路 27 Oct 2026
